Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 16/20 | 0.60 |
| ▸ | PGR | P06401 | 5/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836599 | 0.88 | NR3C1 (0.55) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL1542061 | 0.88 | NR3C1 (0.55) | NR3C1PGRCYP11B2SMO | |
| SCHEMBL1363835 | 0.88 | NR3C1 (0.57) | NR3C1PGRCYP1A2POLBCYP2D6 | |
| SCHEMBL15813253 | 0.84 | NR3C1 (0.52) | NR3C1PGRCYP1A2POLBCYP2D6 | |
| SCHEMBL31221968 | 0.84 | NR3C1 (0.52) | NR3C1PGRCYP1A2POLBCYP2D6 | |
| SCHEMBL1361803 | 0.84 | NR3C1 (0.52) | NR3C1PGRSMO | |
| SCHEMBL22225746 | 0.83 | NR3C1 (0.74) | NR3C1PGRCYP11B2 | |
| SCHEMBL15826159 | 0.83 | NR3C1 (0.51) | NR3C1PGRSMO | |
| SCHEMBL25800348 | 0.82 | NR3C1 (0.60) | NR3C1PGRTSHRSMN1; SMN2CYP11B2 | |
| SCHEMBL30375949 | 0.82 | NR3C1 (0.60) | NR3C1PGRTSHRSMN1; SMN2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 92/4885CYP1A2 203/4885 |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 92/4885CYP1A2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.